1. Scrip

TauRx Attempts Anti-Tau Comeback But Keeps Data Under Wraps

Following 2016 Alzheimer’s Fail

 
• By Ayisha Sharma

The firm has revealed its anti-tau candidate showed promise in a late-stage Alzheimer’s study several years after a disappointing failure, but data are yet to be announced in full.   

Alzheimer's Is Caused By The Abnormal Build-Up Of Protein In Brain Cells • Source: Alamy

TauRx Therapeutics Ltd.’s tau aggregation inhibitor candidate for Alzheimer’s has improved cognitive and functional decline rates according to initial data from a late-stage trial but the lack of numbers leaves room for skepticism given the product’s past.

The Singaporean biotech claimed patients treated with hydromethylthionine mesylate (HMTM) saw decline at a rate substantially lower than is typical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By Manas Mishra

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 
• By Sushmita Panda

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 
• By Dexter Jie Yan

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.